Zacks Investment Research Downgrades Tabula Rasa HealthCare Inc (TRHC) to Sell

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

According to Zacks, “Tabula Rasa HealthCare, Inc. is a provider of patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The company’s cloud-based software applications including EireneRx and MedWise Advisor which provide solutions to payers, providers and other healthcare organizations. Tabula Rasa HealthCare, Inc. is based in NJ, United States. “

Other equities research analysts also recently issued research reports about the company. Stifel Nicolaus raised their price target on Tabula Rasa HealthCare from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, March 14th. Robert W. Baird set a $17.00 price target on Tabula Rasa HealthCare and gave the company a “buy” rating in a research report on Thursday, January 19th. Finally, Piper Jaffray Companies raised their price target on Tabula Rasa HealthCare from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Tuesday, March 14th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Tabula Rasa HealthCare has an average rating of “Buy” and an average price target of $17.50.

Shares of Tabula Rasa HealthCare (NASDAQ:TRHC) traded down 3.48% during midday trading on Friday, hitting $13.02. The company had a trading volume of 52,199 shares. The firm’s 50-day moving average is $13.38 and its 200-day moving average is $13.54. Tabula Rasa HealthCare has a 12-month low of $10.39 and a 12-month high of $16.85. The firm’s market capitalization is $222.29 million.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings results on Monday, March 13th. The company reported $0.10 EPS for the quarter, missing the Zacks’ consensus estimate of $0.11 by $0.01. The firm earned $27.30 million during the quarter, compared to analysts’ expectations of $25.53 million. Tabula Rasa HealthCare’s revenue for the quarter was up 37.9% compared to the same quarter last year. On average, analysts predict that Tabula Rasa HealthCare will post $0.41 earnings per share for the current fiscal year.

WARNING: “Zacks Investment Research Downgrades Tabula Rasa HealthCare Inc (TRHC) to Sell” was originally published by BBNS and is the property of of BBNS. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://baseballnewssource.com/markets/tabula-rasa-healthcare-inc-trhc-cut-to-sell-at-zacks-investment-research-2-updated-updated/525567.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. DIAM Co. Ltd. bought a new position in Tabula Rasa HealthCare during the third quarter valued at approximately $136,000. Laurion Capital Management LP bought a new position in Tabula Rasa HealthCare during the third quarter valued at approximately $430,000. State Street Corp bought a new position in Tabula Rasa HealthCare during the fourth quarter valued at approximately $611,000. Russell Investments Group Ltd. bought a new position in Tabula Rasa HealthCare during the fourth quarter valued at approximately $875,000. Finally, Taylor Wealth Management Partners bought a new position in Tabula Rasa HealthCare during the third quarter valued at approximately $2,458,000. Hedge funds and other institutional investors own 23.79% of the company’s stock.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

5 Day Chart for NASDAQ:TRHC

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tabula Rasa HealthCare Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare Inc and related companies with our FREE daily email newsletter.

 


Latest News

Gift Ngoepe Becomes First African to Play in MLB
Gift Ngoepe Becomes First African to Play in MLB
Eric Thames Pulled From Game With Tightness in Hamstring
Eric Thames Pulled From Game With Tightness in Hamstring
Julio Urias Returning to Dodgers Thursday
Julio Urias Returning to Dodgers Thursday
Tony Gwynn Jr. Like Father Like Son in Baseball and Brewing
Tony Gwynn Jr. Like Father Like Son in Baseball and Brewing
Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Colorado Rockies Bullpen Helping Them to NL West Lead
Colorado Rockies Bullpen Helping Them to NL West Lead


Leave a Reply

 
© 2006-2017 BBNS.